Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus PROGESTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus PROGESTERONE.
CURRETAB vs PROGESTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Progesterone binds to progesterone receptors (PR-A and PR-B) in target tissues, modulating gene expression to induce secretory changes in the endometrium, support pregnancy, and regulate gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
Oral: 200-400 mg daily in 1-2 divided doses; Intramuscular: 50-100 mg daily; Vaginal: 200-400 mg daily in 1-2 divided doses.
None Documented
None Documented
Clinical Note
moderateMedroxyprogesterone acetate + Digoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Digitoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digitoxin
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Elimination half-life: approximately 5-15 minutes for intravenous progesterone; terminal half-life of metabolites (pregnanediol) is about 2-8 hours, but clinical effects (e.g., endometrial transformation) persist for days due to receptor-mediated activity.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Renal (50-60% as metabolites) and fecal (10-20%). Biliary excretion of metabolites occurs; enterohepatic recirculation may contribute to prolonged presence. Unchanged drug negligible in urine.
Category C
Category D/X
Progestin
Progestin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digitoxin."